Macitentan
Active ingredient: Macitentan
In short: Macitentan tablets are an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults to reduce the risks of disease progression and hospitalization for PAH. Effectiveness was established in a long-term study in PAH patients with p
What is Macitentan used for?
Macitentan tablets are an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults to reduce the risks of disease progression and hospitalization for PAH.
Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II to III symptoms treated for an average of 2 years. Patients had idiopathic and heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%) .
ā Boxed warning (FDA's strongest warning)
Macitentan is contraindicated for use during pregnancy because it may cause fetal harm based on animal data [see Contraindications (4.1), Warnings and Precautions (5.1), Use in Specific Populations (8.1)].
Therefore, for females of reproductive potential, exclude pregnancy before the start of treatment with macitentan. Advise use of effective contraception before the initiation of treatment, during treatment, and for one month after stopping treatment with macitentan . When pregnancy is detected, discontinue macitentan as soon as possible .
Macitentan dosage
The recommended dosage of macitentan tablets are 10 mg once daily for oral administration. Doses higher than 10 mg once daily have not been studied in patients with PAH and are not recommended.
Exclude pregnancy before initiating treatment with macitentan tablets in females of reproductive potential [see Boxed Warning, Contraindications (4.1), Warnings and Precautions (5.1), and Use in Specific Populations (8.3)].
How to take Macitentan ā instructions & advice from the label
Advise patient to read FDA-approved patient labeling (Medication Guide).
Embryo-Fetal Toxicity
Counsel female patients of reproductive potential about the need to use effective methods of contraception prior to initiation of treatment with macitentan, during treatment and for one month after treatment discontinuation. Females of reproductive potential should have a negative pregnancy test prior to treatment with macitentan .
Patients should be instructed to contact their physician if they suspect they may be pregnant. Patients should seek additional contraceptive advice from a gynecologist or similar expert as needed.
Educate and counsel females of reproductive potential on the use of emergency contraception in the event of unprotected sex or contraceptive failure.
Advise pre-pubertal females to report any changes in their reproductive status immediately to her prescriber.
Review the Medication Guide with female patients.
Lactation
Advise women not to breastfeed during treatment with macitentan .
Hepatotoxicity
Some members of this pharmacological class are hepatotoxic. Educate patients on signs of hepatotoxicity. ā¦
Warnings & precautions
Do not take this medicine if: Macitentan may cause fetal harm when administered to a pregnant woman. Macitentan is contraindicated in females who are pregnant. Macitentan was consistently shown to have teratogenic effects when administered to animals. If macitentan is used during pregnancy, advise the patient of the potential risk to a fetus .
Macitentan is contraindicated in patients with a history of a hypersensitivity reaction to macitentan or any component of the product .
Based on data from animal reproduction studies, macitentan may cause fetal harm when administered to a pregnant patient and is contraindicated during pregnancy. The available human data for ERAs do not establish the presence or absence of major birth defects related to the use of macitentan. Advise patients who can become pregnant of the potential risk to a fetus. Obtain a pregnancy test prior to initiation of therapy with macitentan. Advise patients who can become pregnant to use effective contraceptive methods prior to initiation of treatment, during treatment, and for one month after discontinuation of treatment with macitentan. When pregnancy is detected, discontinue use as soon as possible [see Dosage and Administration (2.2), Contraindications (4.1), and Use in Specific Populations (8.1, 8.3)].
ERAs have caused elevations of aminotransferases, hepatotoxicity, and liver failure. The incidence of elevated aminotransferases in the study of macitentan in PAH is shown in Table 1.
Table 1: Incidence of Elevated Aminotransferases in the SERAPHIN Study
Macitentan
Tablets 10 mg
(N=242) | Placebo
(N=249)
>3 x ULN | 3.4% | 4.5%
>8 x ULN | 2.1% | 0.4%
In the placebo-controlled study of macitentan, discontinuations for hepatic adverse events were 3.3% in the macitentan 10 mg group vs. 1.6% for placebo. ā¦
Macitentan side effects
Clinically significant adverse reactions that appear in other sections of the labeling include:
Embryo-fetal Toxicity
Hepatotoxicity
Fluid Retention
Decrease in Hemoglobin
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Safety data for macitentan were obtained primarily from one placebo-controlled clinical study in 742 patients with PAH (SERAPHIN study) .
The exposure to macitentan in this trial was up to 3.6 years with a median exposure of about 2 years (N=542 for 1 year; N=429 for 2 years; and N=98 for more than 3 years). The overall incidence of treatment discontinuations because of adverse events was similar across macitentan 10 mg and placebo treatment groups (approximately 11%).
Table 2 presents adverse reactions more frequent on macitentan than on placebo by ā„3%.
Table 2: Adverse Reactions
Adverse Reaction | Macitentan Tablets 10 mg
(N=242)
(%) | Placebo
(N=249)
(%)
Anemia | 13 | 3
Nasopharyngitis/pharyngitis | 20 | 13
Bronchitis | 12 | 6
Headache | 14 | 9
Influenza | 6 | 2
Urinary tract infection | 9 | 6
The following adverse reactions have been identified during post-approval use of macitentan. ā¦
Drug interactions
Strong inducers of CYP3A4 such as rifampin significantly reduce macitentan exposure. Concomitant use of macitentan with strong CYP3A4 inducers should be avoided .
Concomitant use of strong CYP3A4 inhibitors like ketoconazole approximately double macitentan exposure. Many HIV drugs like ritonavir are strong inhibitors of CYP3A4. Avoid concomitant use of macitentan with strong CYP3A4 inhibitors . Use other PAH treatment options when strong CYP3A4 inhibitors are needed as part of HIV treatment .
Concomitant use of moderate dual inhibitors of CYP3A4 and CYP2C9 such as fluconazole is predicted to increase macitentan exposure approximately 4-fold based on physiologically based pharmacokinetic (PBPK) modeling. Avoid concomitant use of macitentan with moderate dual inhibitors of CYP3A4 and CYP2C9 (such as fluconazole and amiodarone) .
Concomitant treatment of both a moderate CYP3A4 inhibitor and moderate CYP2C9 inhibitor with macitentan should also be avoided .
About this medicine
Macitentan is an endothelin receptor antagonist. The chemical name of macitentan is N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide. It has a molecular formula of C19H20Br2N6O4S and a molecular weight of 588.27. Macitentan is achiral and has the following structural formula:
Macitentan is a white to off-white color solid that is soluble in dichloromethane, ethyl acetate and practically insoluble in water. In the solid state macitentan is very stable, is not hygroscopic, and is not light sensitive.
Macitentan tablets are available as a 10 mg film-coated tablet for once daily oral administration. The tablets include the following inactive ingredients: crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, polysorbate 80, povidone. The tablets are film-coated with a coating material containing polyvinyl alcohol, soya lecithin, talc, titanium dioxide, and xanthan gum. ā¦
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a654726e-f12f-4b03-8bfe-727f26761dce. Read the full official label on DailyMed.
Related medicines
Amlodipine Lisinopril Metoprolol Hydrochlorothiazide Tamsulosin Carvedilol Potassium Chloride Spironolactone